Innocan Pharma Covid-19 Exosomes CBD
Covid-19 Exosomes CBD
InnoCan Pharma Ltd. has entered into a sponsored research agreement dated April 17, 2020 with Tel Aviv University (“Ramot”) to collaborate and develop a novel, revolutionary approach to treat COVID-19 by using Cannabidiol (CBD) loaded Exosomes (“ICLX“).
InnoCan has agreed to fund the research based on agreed milestones, in the aggregate amount of approximately US $450,000 for the first stage.
CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells.
This product is expected to be administrated by inhalation.
Innocan Pharma CBD Covid-19 Exosomes
When the cell healing properties of the exosomes are combined with the anti-inflammatory properties of CBD, it is expected to reach high synergetic effect. The research results may be beneficial to additional treatments for Central Nerve System ( CNS ) indications such as epilepsy and Alzheimer’s Disease.
Research Agreement also gives InnoCan Pharma the exclusive option to receive an exclusive worldwide royalty-bearing license to Ramot’s background technology and the research results to allow InnoCan to develop and manufacture ICLX for the treatment of COVID-19 and potentially for other types of lung inflammations and additional respiratory related illnesses.